Get the Stockscreener App
4.056
3.44%
0.136
Anavex Life Sciences Corporation stock is traded at $4.056, with a volume of 203.95K.
It is up +3.44% in the last 24 hours and down -12.61% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$3.92
Open:
$3.98
24h Volume:
203.95K
Relative Volume:
0.08
Market Cap:
$376.25M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-7.1158
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
-1.10%
1M Performance:
-12.61%
6M Performance:
-61.60%
1Y Performance:
-52.13%
1-Day Range:
$3.94
$4.07
1-Week Range:
$3.745
$4.54
52-Week Range:
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.06 | 363.27M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.64 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.01 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.76 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.60 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.38 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Singapore
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript - Insider Monkey
Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) - Yahoo Finance
D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences reports fiscal 2026 first quarter financial results and provides business update - marketscreener.com
Anavex Life Sciences Q1 Earnings Call Highlights - Yahoo Finance
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot - marketscreener.com
Anavex Life Sciences : Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update - marketscreener.com
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
Chipmakers Recap: Does Unity Bancorp Inc meet Warren Buffetts criteriaJuly 2025 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Anavex Life Sciences (AVXL) Price Target Decreased by 25.00% to 33.66 - MSN
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock - Investing.com
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock By Investing.com - Investing.com Nigeria
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - MarketBeat
Trading Action: Can Anavex Life Sciences Corp weather a recessionDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Returns Recap: Why Anavex Life Sciences Corp. stock could rally in 2025Market Risk Report & Momentum Based Trading Ideas - Bộ Nội Vụ
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Anavex Life Sciences
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Eastern Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - Eastern Progress
Why Anavex Life Sciences Corp. stock could rally in 2025Portfolio Update Report & Free Community Consensus Stock Picks - Улправда
Will Anavex Life Sciences Corp. stock continue upward momentumPortfolio Gains Summary & Technical Pattern Recognition Alerts - Улправда
Franklin Credit Management CorporationAVXL ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - FinancialContent
When Will Anavex Life Sciences Corp. (NASDAQ:AVXL) Turn A Profit? - 富途牛牛
Is Anavex Life Sciences Corp. stock a buy for dividend growth2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Anavex Life Sciences Appoints Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology - citybiz
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Anavex Life Sciences
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Shares Surge on Encouraging Regulatory Development - AD HOC NEWS
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Anavex Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL - Chartmill
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):